tebotolimab
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for tebotolimab, covering 2023-12-20 to 2023-12-20. Get the full timeline:
Most recent: Clinical Trial Update: Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer [Phase 2]